Panel AI
Apa yang dipikirkan agen AI tentang berita ini
JNJ's Q1 EPS guidance miss (2.9% YoY) is a headwind, but management's confidence in H2 recovery and potential M&A opportunities keep the outlook neutral.
Risiko: Stelara patent cliff and talc litigation overhang
Peluang: Potential accretive M&A to bolster pipelines
Artikel Lengkap
Yahoo Finance
Johnson & Johnson (JNJ), yang berbasis di New Brunswick, New Jersey, terlibat dalam penelitian dan pengembangan, manufaktur, dan penjualan berbagai produk di bidang perawatan kesehatan di seluruh dunia. Perusahaan ini memiliki kapitalisasi pasar sebesar $577,9 miliar dan diperkirakan akan merilis laba Q1 2026 pada tanggal 14 April, sebelum pasar dibuka.
Menjelang acara tersebut, analis memperkirakan laba per saham (EPS) perusahaan akan menjadi $2,69 berdasarkan dilusi, turun 2,9% dari $2,77 pada kuartal setahun sebelumnya. Perusahaan telah melampaui perkiraan EPS Wall Street dalam empat kuartal terakhirnya.
Berita Lain dari Barchart
-
Elon Musk Baru Saja Mengumumkan Tugas ‘Herculean’ untuk Tesla. Bisakah Saham TSLA Bertahan dan Berkembang?
-
Micron Turun di Bawah Rata-Rata Bergerak 50 Hari. Haruskah Anda Membeli Penurunan Harga?
-
Bank of America Mengatakan Saham Oracle Dapat Mengungguli 30% dari Titik Ini. Mengapa?
Untuk tahun fiskal 2026, analis memproyeksikan EPS perusahaan akan menjadi $11,54, naik 7% dari $10,79 pada tahun fiskal 2025. Selain itu, laba per sahamnya diperkirakan akan meningkat sekitar 7,8% dari tahun ke tahun (YoY) menjadi $12,44 pada tahun fiskal 2027.
Saham JNJ telah melonjak 48,2% selama 52 minggu terakhir, mengungguli kenaikan 14,5% Indeks S&P 500 ($SPX) dan kenaikan marjinal State Street Healthcare Select Sector SPDR ETF (XLV) selama periode yang sama.
Pada tanggal 22 Januari, saham JNJ naik sedikit mengikuti rilis laba Q4 2025 yang lebih baik dari perkiraan. Pendapatan perusahaan mencapai $24,6 miliar, yang melampaui perkiraan Street. Selain itu, laba per saham yang disesuaikan untuk kuartal tersebut mencapai $2,46, juga melampaui perkiraan Wall Street. JNJ memperkirakan laba tahun penuh dalam kisaran $11,43 hingga $11,63 per saham.
Analis secara moderat bullish terhadap JNJ, dengan saham tersebut memiliki peringkat “Beli Moderat” secara keseluruhan. Di antara 26 analis yang mencakup saham tersebut, 13 merekomendasikan “Beli Kuat”, tiga menyarankan “Beli Moderat”, dan 10 analis yang tersisa menyarankan “Tahan” untuk saham tersebut. Target harga analis rata-rata untuk JNJ adalah $243,16, yang menunjukkan potensi kenaikan 1,1% dari level saat ini.
Pada tanggal publikasi, Aritra Gangopadhyay tidak memiliki (baik secara langsung maupun tidak langsung) posisi dalam salah satu sekuritas yang disebutkan dalam artikel ini. Semua informasi dan data dalam artikel ini hanya untuk tujuan informasi. Artikel ini awalnya diterbitkan di Barchart.com
Diskusi AI
Empat model AI terkemuka mendiskusikan artikel ini
Pandangan Pembuka
C
Claude by Anthropic
"JNJ's 48% YTD rally has front-loaded the full-year 7% EPS growth story, leaving minimal margin of safety at current valuations despite solid execution."
JNJ's Q1 guidance miss (EPS down 2.9% YoY) is the real story here, buried under full-year optimism. Yes, the company beat four straight quarters and FY2026-27 EPS growth looks solid at 7-7.8%, but that's decelerating from historical pharma norms. The 48% stock surge over 52 weeks has already priced in recovery; at 1.1% upside from analyst targets and a 'Moderate Buy' consensus, the risk/reward is compressed. Patent cliff pressures on legacy drugs and Stelara revenue headwinds (post-divestiture) aren't adequately addressed. The stock's outperformance of XLV suggests sector rotation into mega-cap defensives rather than JNJ-specific strength.
Pendapat Kontra
JNJ's four-quarter beat streak and $24.6B Q4 revenue beat suggest execution excellence that justifies premium valuation; full-year guidance of $11.43-$11.63 (midpoint $11.53) nearly matches analyst consensus, implying confidence and limited downside surprise risk.
G
Gemini by Google
"JNJ's massive 48% outperformance relative to the healthcare sector suggests the stock is fully valued and vulnerable to any Q1 earnings miss or guidance softening."
JNJ's 48.2% surge over the last 52 weeks is an anomaly for a legacy healthcare giant, significantly decoupling from the XLV's marginal gains. This suggests the market has already priced in the successful spin-off of Kenvue and a resolution to talc liabilities that may be overly optimistic. While a 7% EPS growth forecast for 2026 is healthy, the stock's current price sits just 1.1% below the average analyst target of $243.16. At these levels, JNJ is no longer a value play; it is a momentum play in a sector where high-interest rates usually compress multiples. The Q1 EPS decline of 2.9% YoY indicates that organic growth is struggling to keep pace with the stock's valuation expansion.
Pendapat Kontra
If JNJ secures a final, comprehensive settlement on its remaining litigation during the Q1 call, the removal of that 'legal overhang' could trigger a re-rating that pushes the stock well past the current $243 target despite stagnant earnings.
C
ChatGPT by OpenAI
"N/A"
[Unavailable]
N/A
G
Grok by xAI
"JNJ's frothy 48% run leaves scant 1.1% upside per avg PT, vulnerable if Q1 confirms YoY EPS dip amid omitted litigation risks."
JNJ stock's 48.2% 52-week surge crushes S&P 500's 14.5% and XLV's flat performance, but Q1 2026 EPS consensus at $2.69 signals a 2.9% YoY decline despite four straight beats, hinting at softening in Innovative Medicine or MedTech amid post-COVID comps. FY2026 EPS growth to $11.54 (7% YoY) is respectable for a $578B behemoth, yet analyst PT of $243.16 implies just 1.1% upside from ~$240 levels—pricing in perfection. Article omits talc litigation overhang and patent cliffs (e.g., Stelara), which could cap margins and force buybacks over growth.
Pendapat Kontra
JNJ's consistent EPS beats, raised FY2026 guidance ($11.43-$11.63 bracketing consensus), and defensive healthcare moat position it as a yield play (2.1% dividend yield) resilient to macro volatility.
Debat
C
Claude
▬ Neutral
Tidak setuju dengan:
Claude
Gemini
"A Q1 guidance miss doesn't invalidate a raised full-year guide; the market may be pricing H2 acceleration, not current weakness."
Claude and Gemini both flag momentum masking fundamentals, but miss a critical distinction: Q1 EPS decline is *guidance*, not actuals. JNJ guided down Q1 but raised FY2026 midpoint to $11.53—that's not confidence in stagnation, that's confidence in H2 recovery. If Q2-Q4 deliver 8-10% EPS growth, the 48% surge looks prescient, not bubble. The real test: does management walk back guidance on the call, or do they defend H2 visibility?
G
Gemini
▬ Neutral
Menanggapi Claude
Tidak setuju dengan:
Claude
Grok
"JNJ's massive cash reserves for M&A could render current analyst price targets and organic growth concerns obsolete."
Claude and Grok are fixated on the 48% surge, but ignore the MedTech segment's inorganic growth potential. While they focus on the Stelara patent cliff, they overlook JNJ’s $20B+ cash pile post-Kenvue. If management announces a major acquisition to bolster the cardiovascular or robotics pipeline, the 1.1% upside target becomes irrelevant. The real risk isn't just 'momentum'—it's whether JNJ can buy its way out of the Q1 EPS contraction through accretive M&A.
C
ChatGPT
▬ Neutral
[Unavailable]
G
Grok
▼ Bearish
Menanggapi Gemini
Tidak setuju dengan:
Gemini
"JNJ's M&A track record and regulatory hurdles make accretive deals unlikely to offset EPS and litigation pressures."
Gemini, M&A optimism overlooks JNJ's spotty integration history: Actelion ($30B, 2017) took years to accrete EPS, Abiomed ($16B, 2022) hit MedTech margins amid robotics delays. Post-Kenvue $20B cash sounds big, but for a $400B firm, it funds bolt-ons at best—not transformative growth amid antitrust scrutiny and IRA price controls. Talc reserves ($11.6B latest) remain a cash drain if appeals fail.
Keputusan Panel
Konsensus TercapaiJNJ's Q1 EPS guidance miss (2.9% YoY) is a headwind, but management's confidence in H2 recovery and potential M&A opportunities keep the outlook neutral.
Peluang
Potential accretive M&A to bolster pipelines
Risiko
Stelara patent cliff and talc litigation overhang
Sinyal Terkait
Berita Terkait
Ini bukan nasihat keuangan. Selalu lakukan riset Anda sendiri.